Joseph Tuscano
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Joseph Tuscano sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Joseph Tuscano: 9 sponsored US clinical trials, 5 recruiting.
Joseph Tuscano sponsors 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, with 2 trials.
Top-decile sponsor footprint
Joseph Tuscano ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
NCT06854159
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT06905509
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
NCT05600686
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
NCT04450173
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
NCT04587687
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
NCT02542657
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
NCT04578600
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma
NCT01716208
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
NCT01736943
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
Therapeutic Areas
What is open in the Joseph Tuscano pipeline
5 recruiting of 9 indexed (56% open); 3 completed (33%).
Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Joseph Tuscano: open-pipeline peers nationwide
Peers matched on 9 registered trials and 56% open enrollment, not the therapeutic-area sidebar.
Joseph Tuscano sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 56% open enrollment (± trial volume)
- Disc Medicine · 56% recruiting · 9 trials
- Heart Rhythm Clinical and Research Solutions · 56% recruiting · 9 trials
- Replimune · 56% recruiting · 9 trials
- MGH Institute of Health Professions · 56% recruiting · 16 trials
Related
What to do with this Joseph Tuscano page
9 registered trials is a research-attention snapshot, not an endorsement of Joseph Tuscano or any single study.
- 5 of Joseph Tuscano's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma is the condition Joseph Tuscano studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Joseph Tuscano pipeline card: 9 registered trials from official public datasets.Report a data error.